OLDAKOWSKI JOSEPH FRANK sold $59K of CLOV

OLDAKOWSKI JOSEPH FRANK (VP OF FINANCE AND CONTROLLER) sold 12,102 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.86 on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · OLDAKOWSKI JOSEPH FRANK
Published Jun 17, 2026, 12:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 12:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale size, price, and post-transaction holdings, but the presence of a pre-arranged 10b5-1 plan limits interpretive value.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing given the 10b5-1 structure.

03

What to watch

Insider sales can be offset by other insider buys or broader institutional flows; this article provides only one officer’s sale and no context on net insider activity.

Relevance 2/10Novelty 4/10Timing: Filed 2026-06-17 (covers sale dated 2026-06-16)

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp. /DE (CLOV).

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health insider Form 4 shows VP of Finance and Controller Joseph Frank Oldakowski sold 12,102 shares at $4.86 on 2026-06-16 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an SEC Form 4 insider transaction and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/operational change.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations, so traders may ignore it.

Key entities

  • CLOV

    Subject of the Form 4 insider transaction disclosure.

  • OLDAKOWSKI JOSEPH FRANK

    VP of Finance and Controller who sold 12,102 shares at $4.86 on 2026-06-16 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.